Group 1: R&D Investment - The company has increased R&D expenses significantly, with 2023 expenses reaching ¥7,026.49 million, up from ¥5,298.07 million in 2022 and ¥4,637.78 million in 2021 [4] - R&D expenses accounted for 13.52% of revenue in 2023, compared to 8.72% in 2022 and 7.97% in 2021 [4] - The company plans to maintain its R&D investment intensity in the coming years [4] Group 2: Product Development and Market Position - The company has a comprehensive project evaluation system for drug development, ensuring feasibility before project initiation [5] - The company’s compound digestive enzyme capsules hold the top market share in China for several consecutive years, with no significant changes expected in 2023 [8] - The company’s revenue and profit grew in 2023, driven by sales increases across multiple therapeutic areas and steady development in CMC and CMO businesses [7] Group 3: Pricing and Market Trends - Prices of major products remained stable in 2023, but there is a potential for price reductions in the Chinese pharmaceutical market that may impact sales [6] - The company is observing a shift towards pre-filled syringes and cartridge systems, which are gradually replacing traditional injection forms [9] Group 4: Regulatory and Expansion Efforts - The company’s subsidiary has received EU GMP certification for its small-volume injection production line, actively seeking clients and orders through international exhibitions and partnerships [10] - The company is not currently considering external expansion through mergers or acquisitions, focusing instead on core business growth [11]
星昊医药(430017) - 投资者关系活动记录表